← Back to Search

Cannabinoid

CBD Oil for Post-Traumatic Stress Disorder

Phase 2
Waitlist Available
Led By Michael J Telch, Ph.D.
Research Sponsored by University of Texas at Austin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meets for a current DSM-5 diagnosis of PTSD as their "primary" mental disorder
Has access to the internet
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-treatment (week 9) and one month (week 13) follow-up assessments
Awards & highlights

Study Summary

This trial is testing if CBD can help people with PTSD by seeing if it improves symptoms and how well they function. There are 3 groups- one receiving CBD isolate, one Broad Spectrum CBD, and a placebo group. They expect that the CBD groups will do better than the placebo group and that the Broad Spectrum group will do better than the Isolate group.

Eligible Conditions
  • Post Traumatic Stress Disorder

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your main mental health condition is Post-Traumatic Stress Disorder (PTSD) as defined by the DSM-5.
Select...
You are able to use the internet.
Select...
You agree not to use any marijuana that is not part of the study during the study period.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-treatment (week 9) and one month (week 13) follow-up assessments
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-treatment (week 9) and one month (week 13) follow-up assessments for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PCL-5
Secondary outcome measures
GAD-7
PHQ-9
PROMIS Alcohol Use -Short Form
+2 more

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: CBD IsolateActive Control1 Intervention
300 mg/day of CBD isolate
Group II: CBD Broad SpectrumActive Control1 Intervention
300 mg/day of CBD Broad Spectrum Oil
Group III: Placebo oilPlacebo Group1 Intervention
Matched Placebo Oil

Find a Location

Who is running the clinical trial?

University of Texas at AustinLead Sponsor
348 Previous Clinical Trials
80,222 Total Patients Enrolled
Michael J Telch, Ph.D.Principal InvestigatorUniversity of Texas at Austin
4 Previous Clinical Trials
301 Total Patients Enrolled

Media Library

CBD Broad Spectrum (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04197102 — Phase 2
Post-Traumatic Stress Disorder Research Study Groups: CBD Isolate, CBD Broad Spectrum, Placebo oil
Post-Traumatic Stress Disorder Clinical Trial 2023: CBD Broad Spectrum Highlights & Side Effects. Trial Name: NCT04197102 — Phase 2
CBD Broad Spectrum (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04197102 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the ultimate goal of this clinical experiment?

"This research is gauging its effectiveness with the CAPS-5 measure during post-treatment (week 9), one month (week 13) and three months (week 21). Secondary outcomes include changes from baseline in symptoms of depression, as assessed by PHQ-9; anxiety, determined using GAD-7; and further evaluation of depressive signs via QIDS assessments."

Answered by AI

Is the minimum age requirement for this research experiment 18 or older?

"This research trial seeks to enroll patients between the ages of 18 and 70. Additionally, there are 58 studies available for minors and 380 trials that focus on elderly individuals."

Answered by AI

Are there any precedents of CBD Isolate being used in prior clinical experiments?

"Presently, 79 CBD Isolate trials are in progress. Out of those studies, 16 have reached Phase 3 status with the bulk being located at Ribeirao Preto, Sao Paulo and 289 other sites across the globe also hosting research initiatives for this treatment."

Answered by AI

Has the United States Food and Drug Administration sanctioned CBD Isolate?

"There is limited data suggesting the safety of CBD Isolate, which resulted in a score of 2 on our scale. This reflects that while there has been some research into its safety, none exists to support its efficacy."

Answered by AI

Are there vacancies left for participants in this experiment?

"Affirmative. Per information on clinicaltrials.gov, the recruitment for this medical exploration is still open. It was initially posted January 15th 2020 and most recently edited October 3rd 2022 with a goal of recruiting 150 patients across one centre."

Answered by AI

What is the enrollment rate for this investigation?

"Affirmative. According to clinicaltrials.gov, this research project is presently recruiting test subjects and was first posted on January 15th 2020 with the last edit being made on October 3rd 2022. The trial necessitates 150 participants from one centre."

Answered by AI

Are there any eligibility criteria for entry into this clinical trial?

"This medical trial is recruiting 150 patients aged 18 to 70 who are suffering from stress or trauma-related disorders. Applicants must meet the DSM-5 criteria for PTSD, be fluent in English, possess transportation and internet access, agree to provide informed consent, and abstain from cannabis use throughout the study period."

Answered by AI

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What site did they apply to?
Laboratory for the Study of Anxiety Disorders, University of Texas at Austin
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
3+
Recent research and studies
~3 spots leftby May 2024